AKT1 and neoplasm: In addition, TAK-242 treatment in vivo was able to reduce BrdU incorporation (29) in ERG-AKT tumors (Figure 6C and Supplementary Figure S2), indicating that proliferation rate is a primary mechanism of the reduced tumor size elicited by TAK-242.